Alphatec (NASDAQ:ATEC) Stock Price Down 5.7% – Time to Sell?

Alphatec Holdings, Inc. (NASDAQ:ATEC)’s stock price traded down 5.7% on Tuesday . The company traded as low as $16.53 and last traded at $16.5820. 1,421,106 shares were traded during trading, a decline of 60% from the average session volume of 3,559,850 shares. The stock had previously closed at $17.59.

Key Headlines Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: ATEC announced an exclusive U.S. partnership with Theradaptive for the OsteoAdapt® regenerative platform — expands Alphatec’s pipeline and long-term optionality in spinal fusion. ATEC and Theradaptive Enter Strategic Partnership
• Positive Sentiment: Preliminary fourth-quarter and full‑year 2025 results showed revenue above consensus (Q4 ~ $212.2–213.2M; FY2025 ~ $763.4–764.4M), supporting near‑term growth credibility. ATEC Announces Select Preliminary Financial Results for 2025
• Positive Sentiment: Analysts at HC Wainwright and Needham reaffirmed “buy” ratings and set price targets ($24 and $22), indicating institutional conviction and sizable upside vs. current levels. Benzinga: Analyst Reaffirms TickerReport: Needham Reaffirmation
• Neutral Sentiment: Needham/TipRanks commentary calls the 2026 guide “conservative” but views strong 2025 momentum and strategic optionality as supportive of a buy rating after the pullback. TipRanks: Conservative 2026 Guide, Strong 2025 Momentum
• Neutral Sentiment: Reported short‑interest data in the feed is effectively zero/invalid and is not a meaningful driver of today’s move.
• Negative Sentiment: Market reaction focused on the tone and conservatism of the FY2026 outlook (and limited EPS detail), prompting profit‑taking and the share price decline despite revenue beats. Investing.com: Alphatec stock tumbles after disappointing 2026 guidance

Analyst Ratings Changes

A number of research analysts have issued reports on ATEC shares. Wall Street Zen raised shares of Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Canaccord Genuity Group upped their price target on Alphatec from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, October 31st. JPMorgan Chase & Co. began coverage on Alphatec in a research note on Friday, October 24th. They issued an “overweight” rating and a $19.00 price objective for the company. Lake Street Capital set a $25.00 target price on Alphatec and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Stifel Nicolaus began coverage on Alphatec in a report on Tuesday, October 28th. They issued a “buy” rating and a $20.00 target price on the stock. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and a consensus target price of $22.82.

Alphatec Price Performance

The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of -15.89 and a beta of 1.01. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 43.02. The company’s 50 day simple moving average is $20.70 and its 200-day simple moving average is $16.46.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.09. The firm had revenue of $196.50 million for the quarter, compared to analysts’ expectations of $182.78 million. The business’s quarterly revenue was up 30.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.28) EPS. On average, equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Scott Lish sold 19,900 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $19.64, for a total value of $390,836.00. Following the completion of the transaction, the chief operating officer directly owned 641,432 shares in the company, valued at approximately $12,597,724.48. This represents a 3.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Craig E. Hunsaker sold 32,584 shares of the firm’s stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $20.84, for a total value of $679,050.56. Following the completion of the sale, the executive vice president directly owned 1,256,558 shares in the company, valued at approximately $26,186,668.72. The trade was a 2.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,403,342 shares of company stock valued at $69,816,381. 22.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alphatec

Large investors have recently bought and sold shares of the stock. Aster Capital Management DIFC Ltd purchased a new stake in shares of Alphatec during the 3rd quarter valued at $34,000. Osterweis Capital Management Inc. purchased a new position in shares of Alphatec in the 2nd quarter worth $37,000. China Universal Asset Management Co. Ltd. acquired a new position in Alphatec in the third quarter valued at $73,000. FNY Investment Advisers LLC purchased a new stake in Alphatec during the third quarter valued at about $74,000. Finally, Nisa Investment Advisors LLC grew its position in Alphatec by 22.4% during the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after acquiring an additional 1,045 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.